Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
9 people get LZAGF.PK articles and Market Currents by email alert.
Get email alerts on LZAGF.PK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
6 Stocks Shining on MondayAlex Shadunsky • Tue, Jul 12, 2011 -
-
-
Pfizer Invests up to $350 Million in Indian Biosimilar DealChinaBio Today • Wed, Oct 20, 2010 -
-
Teva Targets Roche's RituxanThe Burrill Report • Sun, May 30, 2010 -
Biotech's Latest Failed Trials, Mishaps and Missed TargetsThe Burrill Report • Mon, Jan 18, 2010
-
To learn more about Seeking Alpha Pro, click here.
There are no Focus articles on LZAGF.PK.
-
-
-
6 Stocks Shining on MondayAlex Shadunsky • Tue, Jul 12, 2011
-
-
-
Pfizer Invests up to $350 Million in Indian Biosimilar DealChinaBio Today • Wed, Oct 20, 2010
-
-
Teva Targets Roche's RituxanThe Burrill Report • Sun, May 30, 2010
-
Biotech's Latest Failed Trials, Mishaps and Missed TargetsThe Burrill Report • Mon, Jan 18, 2010
-
There are no Transcripts on LZAGF.PK.
There are no News articles on LZAGF.PK.
LZAGF.PK vs. ETF Alternatives
Company Description
Currently, there's no company description for LZAGF.PK.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, July 11, 2011, 4:19 AM Lonza (LZAGF.PK) agrees to buy Arch Chemicals (ARJ) for $1.4B, or $47.20/share, a 37% premium to Arch's average closing price over the last 30 days. The deal, announced this morning, creates the world's largest microbial-control business, but regulators may be more concerned by the 11% spike in Arch's shares on Friday on unusually high volume. Comment! [M&A, Healthcare]
There are no StockTalks on this stock yet.